Designer Brands is a footwear and accessories designer, producer and retailer. The company has three segments: U.S. Retail, which includes stores operated in the U.S. under the DSW Designer Shoe Warehouse banner and its related e-commerce site; Canada Retail, which includes stores operated in Canada under The Shoe Company, Shoe Warehouse, and DSW Designer Shoe Warehouse banners and related e-commerce sites; and Brand Portfolio, which includes sales from wholesale, serving retailers as the design and buying agent for products under private labels, and direct-to-consumer e-commerce sites. The company separates its merchandise into three categories: women's footwear; men's footwear; and accessories and other.

Dril-Quip designs, manufactures, sells and services drilling and production equipment for use in deepwater, harsh environment and severe service applications. The company's products consist of subsea and surface wellheads, subsea and surface production trees, subsea control systems and manifolds, mudline hanger systems, connectors and associated pipe, drilling and production riser systems, liner hangers, wellhead connectors, diverters and safety valves. The company provides technical advisory assistance during installation of its products, as well as rework and reconditioning services. The company's customers may rent or purchase running tools from the company for use in the installation and retrieval of its products.

Safehold is a holding company. Through its subsidiaries, the company operates its business through one segment by acquiring, managing and capitalizing ground leases. Ground leases generally represent the ownership of land underlying commercial real estate properties, which are leased on a long-term basis (base terms are 30 to 99 years, often with tenant renewal options) by the land owner to a tenant that owns and operates the building on top of the land, or what the company refer to as a Safehold?.

Sensient Technologies is a manufacturer and marketer of colors, flavors and fragrances. The company's three reportable segments are: Flavors & Fragrances Group, which develops, manufactures, and supplies flavor and fragrance systems for the food, beverage, personal care, and household-products industries; Color Group, which provides natural and synthetic color systems for use in foods, beverages, pharmaceuticals, and nutraceuticals, colors and other ingredients for cosmetics; and Asia Pacific Group, which provides a range of products from its Flavors & Fragrances Group and Color Group, as well as products developed by regional technical teams to appeal to local preferences.

Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR), bacterial infections. The company's product candidate, SPR994 (tebipenem pivoxil hydrobromide), is designed to be oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. The company also has a platform technology known as its Potentiator Platform, which includes two intravenous-administered agents, SPR206 and SPR741, that are active either alone or in combination with other standard of care agents and are designed to treat MDR Gram-negative bacteria in the hospital.

Stoke Therapeutics is a biotechnology company focused on treating the underlying causes of severe genetic diseases by upregulating protein expression. The company is developing antisense oligonucleotide, medicines that target ribonucleic acid (RNA), and modulate precursor-messenger RNA, splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. The company designed its primary product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epile.

ZIOPHARM Oncology is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing immuno-oncology platforms that utilize cell- and gene-based therapies to treat patients with cancer. The company is developing immuno-oncology platform technologies for the treatment of various cancer types. The company's Sleeping Beauty platform is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T cells outside of the body for subsequent infusion. The company's Controlled IL-12 platform is designed to stimulate expression of interleukin 12, a regulator of the immune system to focus the patient's immune system to attack cancer cells.